



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

• The Honorable John D. Dingell
Chairman
Committee on Energy and Commerce
House of Representatives
Washington, D.C. 20515-6115

AUG 29 2007

Dear Mr. Chairman:

Thank you for your letter of June 20, 2007, co-signed by Bart T. Stupak, Chairman, Subcommittee on Oversight and Investigations, Committee on Energy and Commerce regarding, among other things, the Food and Drug Administration's (FDA) Office of Regulatory Affairs (ORA) proposed transformation.

Your letter requests all records related to the proposed ORA transformation from January 1, 2005, to August 1, 2007. A portion of the requested records is provided as enclosures with this letter and additional documents will be provided to you as soon as they are available.

Certain enclosed documents contain deliberative information protected from disclosure to the public under the Freedom of Information Act (Title 5, United States Code [U.S.C], section 552) and FDA regulations. The Committee should not publish or otherwise make public any such information. We would be glad to discuss with the Committee staff the protected status of any specific information.

Thank you again for contacting us concerning this matter. A similar letter, without enclosures, has been sent to Chairman Stupak. If you have any further questions, please let us know.

Sincerely,



Stephen R. Mason
Acting Assistant Commissioner
For Legislation

Enclosures